How might endotyping guide chronic obstructive pulmonary disease treatment? Current understanding, knowledge gaps and future research needs.
How might endotyping guide chronic obstructive pulmonary disease treatment? Current understanding, knowledge gaps and future research needs.
复制标题
内定型如何指导慢性阻塞性肺疾病的治疗？目前的认识、知识差距和未来的研究需求。
DOI：
10.1097/mcp.0000000000000751
复制
发表时间：
2021-03-01
影响因子：
3.3
通讯作者：
Borchers MT
中科院分区：
文献类型：
--
作者：
Burkes RM;Panos RJ;Borchers MT
这篇综述讨论了针对慢性阻塞性肺疾病（COPD）内型的新兴疗法，或讨论了表现为该疾病的病理生物学过程。特定的内源性疾病已经成为COPD治疗的目标。这些包括嗜酸性粒细胞炎症、白细胞介素-17的过量产生、慢性支气管炎和粘膜性质改变以及慢性感染。针对这些内质型的病因或由此产生的临床表现的治疗方法已经被评估过。虽然一些中间结果看起来很有希望，但还没有发现改变COPD治疗的模式。基础和临床科学家继续定义可以直接治疗的内源性类型。在这篇最新的综述中，还没有一种内源性定向治疗显示出巨大的临床效果。
This review discusses emerging therapies directed at chronic obstructive pulmonary disease (COPD) endotypes, or discussing pathobiological processes that manifest as the disease. Specific endotypes have been targeted in COPD. These include eosinophilic inflammation, overproduction of interleukin-17, chronic bronchitis and altered nature of mucous, and chronic infection. Therapies exactly directed at the cause of these endotypes or their resultant clinical findings have been assessed. While some intermediate outcomes have seemed promising, there have been no findings that shift the paradigm of COPD therapy. Basic and clinical scientists continue to define endotypes that may be directly addressed with therapeutics. As of the time of this up-to-date review, there is yet to be an endotype-directed therapy to demonstrate great clinical effect.